3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
11
Breast
5
Head & Neck
3
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
14
Uterine Cervical Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Fallopian Tube Neoplasms
5
Breast Neoplasms
5
Pancreatic Neoplasms
4
Neoplasms
4
Endometrial Neoplasms
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Vaginal Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Rectal Neoplasms
2
Peritoneal Neoplasms
2
Melanoma
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Urethral Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Interventions
pembrolizumab
17
Paclitaxel
11
Carboplatin
9
Docetaxel
7
Cisplatin
6
Bevacizumab
5
lenvatinib
4
Saline Solution
3
Glucose
2
Brachytherapy
2
trastuzumab deruxtecan
1
olaparib
1
efineptakin alfa
1
camrelizumab
1
Oxaliplatin
1
Injections
1
Gemcitabine
1
Fluorouracil
1
Doxorubicin
1
Capecitabine
1
Axitinib
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Capecitabine
×
Gynecologic
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled